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Abstract
BACKGROUND—The prevalence of esophageal atresia (EA) has been shown to vary across 
different geographical settings. Investigation of geographical differences may provide an insight 
into the underlying etiology of EA.
METHODS—The study population comprised infants diagnosed with EA during 1998 to 2007 
from 18 of the 46 birth defects surveillance programs, members of the International Clearinghouse 
for Birth Defects Surveillance and Research. Total prevalence per 10,000 births for EA was 
defined as the total number of cases in live births, stillbirths, and elective termination of pregnancy 
for fetal anomaly (ETOPFA) divided by the total number of all births in the population.
RESULTS—Among the participating programs, a total of 2943 cases of EA were diagnosed with 
an average prevalence of 2.44 (95% confidence interval [CI], 2.35–2.53) per 10,000 births, 
ranging between 1.77 and 3.68 per 10,000 births. Of all infants diagnosed with EA, 2761 (93.8%) 
were live births, 82 (2.8%) stillbirths, 89 (3.0%) ETOPFA, and 11 (0.4%) had unknown outcomes. 
The majority of cases (2020, 68.6%), had a reported EA with fistula, 749 (25.5%) were without 
fistula, and 174 (5.9%) were registered with an unspecified code.
CONCLUSIONS—On average, EA affected 1 in 4099 births (95% CI, 1 in 3954–4251 births) 
with prevalence varying across different geographical settings, but relatively consistent over time 
and comparable between surveillance programs. Findings suggest that differences in the 
prevalence observed among programs are likely to be attributable to variability in population 
ethnic compositions or issues in reporting or registration procedures of EA, rather than a real risk 
occurrence difference.
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INTRODUCTION
Esophageal atresia (EA) is the most frequent anomaly of the esophagus and is characterized 
by the complete discontinuity of the esophagus with or without an abnormal connection 
between the esophagus and the trachea—tracheo-esophageal fistula (TEF). Diagnosis occurs 
prenatally or, in most cases, at birth and surgical repair is required in the first few days of 
life. Although the etiology of EA is largely unknown (Felix et al., 2009), geographic, 
temporal, and ethnic variations have been reported.
The prevalence of EA has been shown to vary across and within different geographical 
settings with a study from five regions in Britain reporting estimates ranging between 0.7 
and 3.2 per 10,000 births (Rankin et al., 2005), although EA cases in that study also included 
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those with esophageal stenosis. Similarly, differences in rates among areas in the United 
States have been reported with a prevalence of 2.24 in Hawaii (Forrester and Merz, 2005), 
2.33 in Texas (Ethen and Canfield, 2002), and 2.82 per 10,000 births in California (Torfs et 
al., 1995); among European countries, prevalence has been reported for Iceland (1.83 per 
10,000; Gunnarsdottir et al., 2004), Strasbourg, France (2.96 per 10,000; Stoll et al., 2009), 
and the United Kingdom Northern Region (3.13 per 10,000 births; Sparey et al., 2000). 
Given that EA is a rare condition, small numbers may also have a potential effect on rates. 
Ethnic composition of a population may also influence EA prevalence, with lower rates 
noted among Hispanic and African American communities (Carmichael et al., 2004; 
Forrester and Merz, 2005).
International differences in the prevalence of EA across different geographical regions may 
also be attributable to differences in case identification methods, case definition, and case 
ascertainment.
Best estimates of prevalence of major birth defects, based on international data, are 
important to serve as a reference point for the evaluation of individual, regional, or national 
surveillance programs and to identify geographical regions of higher or lower than expected 
prevalence (Leoncini et al., 2008; Cocchi et al., 2010). Investigation of geographical 
differences may also provide an insight into the underlying etiology of EA. The aim of this 
study was to investigate the international prevalence of EA among birth defects surveillance 
programs in North and South America, Europe, and Australia and provide a worldwide 
collective estimate.
MATERIALS AND METHODS
Data for this study were sourced from 18 birth defects surveillance programs, all members 
of the International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR). 
Programs who agreed to participate provided relevant data on EA among live births, 
stillbirths, and elective termination of pregnancy for fetal anomaly (ETOPFA), if permitted. 
All participating programs were also required to have a stable methodology of ascertainment 
and registration over the 10-year study period of 1998 to 2007. The following programs 
provided data for slightly different years: Slovak Republic, 2001 to 2007; Texas, 1997 to 
2006; and Utah, 1999 to 2007.
The main characteristics of the 18 participating programs in this study are reported in Table 
1, with additional details available from the annual reports of the ICBDSR (http://
www.icbdsr.org; International Clearing-house for Birth Defects Surveillance and Research, 
2008) and the National Birth Defects Prevention Network (http://www.nbdpn.org; National 
Birth Defects Prevention Network, 2008), and from selected publications from individual 
programs (Mutchinick et al., 1988; Czeizel, 1997; Correa-Villasenor et al., 2003; Castilla 
and Orioli, 2004; De Vigan et al., 2005; Feldkamp et al., 2005; Bower et al., 2009; Lowry 
RB et al., 2009).
Classification of cases was undertaken by each individual program using either the British 
Pediatric Association International Classification of Diseases (ICD) coding system (ICD9-
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BPA) or ICD10. For this study, EA cases included all reported infants and fetuses diagnosed 
with an esophageal atresia with TEF (ICD9-BPA: 750.31, 750.33; ICD10: Q39.1) or without 
TEF (ICD9-BPA: 750.30; ICD10: Q39.0) or unspecified EA (750.3). Other types of EA 
including TEF without atresia (ICD9-BPA: 750.32; ICD10: Q39.2), esophageal stenosis, or 
esophageal web (ICD9-BPA: 750.34, 750.35; ICD10: Q39.3, Q39.4) were considered 
separately.
Total prevalence per 10,000 births was defined as the total number of cases among live 
births, stillbirths, and ETOPFA divided by the total number of all births (live births and 
stillbirths) in the population. Spontaneous abortions were not considered. We used the term 
total prevalence instead of prevalence or birth prevalence to underline that ETOPFA was 
also included. To validate the total prevalence, we undertook a sensitivity analysis by 
comparing overall total prevalence to estimated result for six programs previously shown to 
have good ascertainment of birth defects (Leoncini et al., 2010). Ninety-five percent 
confidence intervals (CIs) for prevalence were calculated based on the Poisson distribution. 
Chi-square test for trend was used to evaluate homogeneity and time trend of the prevalence 
in the study period. Statistical analyses were performed using Stata 9.0 (Stata Corporation, 
College Station, TX) and SAS 9.1 (SAS Institute, Cary, NC), with p < 0.05 considered 
statistically significant.
RESULTS
Among the eighteen surveillance programs of the ICBDSR, a total of 2943 cases of EA were 
registered between 1998 and 2007 (Table 2). The majority of cases (2020, 68.6%) had a 
reported esophageal atresia with fistula, 749 cases (25.5%) were without fistula, and 174 
cases (5.9%) were unspecified. The total prevalence of EA was 2.44 (95% CI, 2.35–2.53) 
per 10,000 births; and on average, EA affected 1 in 4099 births (95% CI, 3954–4251 births). 
The prevalence ranged from 1.77 (95% CI, 1.52–2.06) per 10,000 births in Hungary and 
Atlanta to 3.68 (95% CI, 3.41–3.97) in South America (Table 2). Sensitivity analysis using 
data from programs with optimal ascertainment of cases revealed that total prevalence of EA 
was 2.47 per 10,000 births.
Overall, the average annual trend in EA remained fairly constant over the study period 
varying between 2.32 in 1998 to 2.60 per 10,000 births in 2007, and there was no evidence 
of a significant linear trend in EA among each of the programs (data not shown). However, 
there was a modest decline in the trend of EA in Alberta and Dublin, and a slight increase in 
cases in Western Australia, Mexico, and Israel.
Of all infants with a diagnosis of EA, there were 2761 (93.8%) live births, 82 (2.8%) 
stillbirths, 89 (3.0%) ETOP-FAs, and 11 (0.4%) with unspecified outcome. Programs in 
Dublin and Alberta had a relatively higher proportion of stillbirths (14.0% and 11.4%, 
respectively); in the case of ETOPFA, two programs (i.e., Central East, France and Wales) 
reported one in five cases that resulted in a termination of pregnancy (Fig. 1). Excluding 
ETOPFA, the total prevalence of EA reduced slightly to 2.37 (95% CI, 2.28–2.45) per 
10,000 births.
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The total prevalence of TEF without atresia was 0.22 per 10,000 births (95% CI, 0.19–0.24; 
1 in every 46,398 births). Compared with EA, TEF without atresia was reported much less 
frequently (<0.5 per 10,000 births) by all members of ICBDSR except for Western 
Australia, where the prevalence was 1.3 per 10,000 births. Cases of esophageal stenosis or 
esophageal web (n = 44) occurred rarely, 1 in every 274,170 births (0.04 per 10,000 births), 
but was more commonly diagnosed in Saxony–Anhalt, Germany (0.12 per 10,000 births) 
compared with all other surveillance programs.
DISCUSSION
Esophageal atresia affects an average of 1 in every 4099 births, with a total prevalence of 
2.44 (95% CI, 2.35–2.53) per 10,000 births among 18 birth defects surveillance program 
members of the ICBDSR. The prevalence ranged between 1.77 and 3.68 per 10,000 births 
among members representing North and South America, Europe, and Australia. However, 
sensitivity analysis limiting data to member programs with optimal case ascertainment 
revealed an almost identical total prevalence (2.47). The findings are also similar to an 
earlier study of EA among nine ICBDSR programs reporting a prevalence of 2.56 per 
10,000 births from 1965 to 1989 (Robert et al., 1993).
Findings from other congenital anomaly surveillance programs such as EUROCAT (the 
European surveillance of congenital anomalies working group) reported a comparable 
prevalence of 2.46 per 10,000 births among 23 member registries for the years 1997 to 2006 
(Pedersen et al., 2012). This analysis included five ICBDSR members from our present 
study. When limiting our data to 10 European members of the ICBDSR, we also found the 
same result (2.44 per 10,000 births). The estimated national prevalence of EA reported by 
the U.S. National Birth Defects Prevention Network was 2.12 per 10,000 births (adjusted for 
race or ethnicity) among 14 member programs for the period from 2004 to 2006. Slight 
differences in prevalence by case ascertainment methods were observed with results ranging 
from 2.17 among 10 programs using active birth defects surveillance to 2.36 among seven 
passive surveillance systems and 2.54 among five passive surveillance programs with a case 
confirmation component (Parker et al., 2010).
Despite the range of geographic locations and study periods, comparison of the total 
prevalence of EA by various international surveillance programs reveals relatively similar 
results with EA diagnosed among 1 in 4099 to 4608 infants. These findings highlight the 
relative stability of the prevalence of EA, internationally and over time. In our international 
study, there was no consistent trend for neighboring countries or states within continents, 
with a small variability in prevalence potentially influenced by chance or differences in 
reporting or surveillance methods, study population, ethnic distribution, or geographical or 
environmental factors. For example, the two programs reporting higher prevalence of EA 
(South America and Israel) may be explained by their hospital-based case ascertainment 
program with active notification by trained clinicians in each hospital. However, higher 
prevalence may also reflect a truly higher rate of EA, and further investigation of these 
results is important. Conversely, slightly lower prevalence of EA reported from surveillance 
programs in Atlanta and Texas may be explained by the ethnic composition of the 
population in these two U.S. states, with almost two thirds of all infants born to African 
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American or Hispanic women, respectively (National Birth Defects Prevention Network, 
2009). Studies of congenital malformations by ethnic groups in the United States have found 
that compared with non-Hispanic white women, Hispanic and African American women had 
a reduced risk of EA without fistula (relative risk, 0.75; 95% CI, 0.62–0.90; and relative 
risk, 0.59; 95% CI, 0.62–0.90; respectively; Carmichael et al., 2004; Forrester and Merz, 
2005). In Hungary, a combination of incomplete registration of cases at birth and 
terminations of pregnancy, and a true lower prevalence may explain their lower estimates.
Although there was some discrepancy among programs in the distribution of specific types 
of EA (with and without TEF), the overall proportions were similar to those reported in the 
literature (Clark, 1999; Shaw-Smith, 2006; Spitz, 2007). These differences may be due to 
variation in classification, identification, or reporting practices across programs rather than 
reflect real differences (Shaw-Smith, 2006; Spitz, 2007). Higher prevalence of TEF without 
atresia in some settings may also be due to increased detection and sources of notification 
such as post mortem evaluation (Bower et al., 2009). Several factors may also influence 
reporting and registration of EA including: screening policies and procedures, clinician 
skills, timing of aneuploidy and fetal anomaly screening, subsequent availability and timing 
of elective termination of pregnancy, and autopsy policies. Previous studies have shown that 
the rate of termination of pregnancy is higher for cases with chromosomal or additional 
congenital anomalies than for cases with an isolated anomaly (Haeusler et al., 2002; Garne 
et al., 2007). Chromosomal anomalies have been reported to occur in 6 to 10% of EA cases 
(Garne et al., 2007; Genevieve et al., 2007; Pedersen et al., 2012); while greater than 50% 
and up to two thirds of infants with EA have additional anomalies (Genevieve et al., 2007; 
Spitz, 2007; de Jong et al., 2010a; Pedersen et al., 2012). Given that EA is more likely to be 
diagnosed in conjunction with other syndromes (particularly VACTERL: Vertebral 
anomalies, Anal atresia, Cardiovascular anomalies, Tracheo-Esophageal fistula, Renal 
and/or Radial anomalies, Limb defects) or chromosomal anomalies that may result in 
termination of pregnancy, it is important to include terminated cases in ascertainment 
(Shaw-Smith, 2006; Felix et al., 2009). For some anomalies, availability and reporting of 
ETOPFA may increase ascertainment of cases. In this study, total prevalence of EA was 
only slightly attenuated to 2.37 per 10,000 births if terminations were excluded. This finding 
was confirmed by a study from Texas that found no effect on estimates of EA when elective 
terminations before 20 weeks’ gestation were included in case ascertainment (Ethen and 
Canfield, 2002).
The underlying etiology of EA has been described as multifactorial and is likely to differ 
across settings (Robert et al., 1993; Felix et al., 2009; de Jong et al., 2010b). In addition to 
maternal ethnicity and geographic location, previous studies have reported EA to be 
associated with maternal age (Leck et al., 1968; Harris et al., 1995), multiple gestation 
(Harris et al., 1995; Riley et al., 1998), infant sex (Robert et al., 1993) and use of assisted 
reproductive technology (Reefhuis et al., 2009). In a recent study of EA in the United States, 
women using assisted reproductive technology had a 4.5-fold increased risk of having an 
infant with EA (Reefhuis et al., 2009). Prevalence of EA has also been found to be higher 
among multiple births compared with singletons (Harris et al., 1995; Riley et al., 1998), and 
increased risk was reported with increasing maternal age (Leck et al., 1968; Harris et al., 
1995). In contrast, a protective effect was found among women who have had three or more 
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births (OR, 0.50; 95% CI, 0.36–0.71; Harris et al., 1995; Carmichael et al., 2004). However, 
given the low frequency of occurrence of most of these factors in the general population, the 
population-attributable risk is likely to be minimal. Variations in ethnicity as detailed above 
may also be surrogates for a number of different exposures, including socioeconomic status, 
nutrition, stress, and access to services. Differences in lifestyle factors, such as smoking or 
dietary habits within countries or regional variation, may also affect estimates. However, 
lack of temporal trends among the included programs suggests environmental factors, which 
change over time, are less likely to play a role in the development of EA (Robert et al., 
1993; Canfield et al., 2006; Garne et al., 2007). Underlying and still unknown (Genevieve et 
al., 2011) genetic susceptibility, biologic or physical differences may also modify risk of 
exposures. Although a number of genetic abnormalities have been associated with EA, no 
specific gene has been implicated (Felix et al., 2009). Further study with more detailed 
information to assess risk factors and underlying characteristics of cases with EA is 
required.
One of the limitations of the study is that it did not collect information on maternal risk 
factors that might help to elucidate the etiology of EA or explain differences in the 
prevalence across settings. Furthermore, we did not collect information to differentiate 
between isolated cases and those with associated (multiple) or chromosomal anomalies 
because of difficulties in standardizing the definition of associated anomalies across 
programs. Despite these limitations, one of the strengths of the study is that case 
identification is likely to be complete because EA is diagnosable either antenatally or at the 
time of birth and require surgical attention. Recent studies from the Netherlands and Oxford, 
U.K., reported that diagnosis of EA occurred prenatally in 38% of infants (Choudhry et al., 
2007; Garne et al., 2007; de Jong et al., 2010a; Pedersen et al., 2012). Postnatally, EAs are 
suspected and diagnosed by respiratory or feeding difficulties and inability to pass a 
nasogastric tube; they are confirmed on chest radiograph with surgical correction within 24 
to 48 hours (Spitz, 2007).
In conclusion, EA affects an average of 1 in every 4099 births worldwide and has remained 
surprisingly stable over time. Although there was some variation in the reported prevalence 
among and within countries, overall EA was also relatively consistent across European and 
American surveillance programs. Findings suggest that differences in the prevalences 
observed among programs are likely to be attributable to local phenomena affecting 
reporting or case registration of EA or ethnic composition, rather than a real difference in 
risk occurrence per se. Future epidemiologic studies accounting for ethnic distribution, 
maternal characteristics, genetic factors, and associated anomalies may provide important 
information regarding the underlying epidemiology of EA.
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Figure 1. 
Proportion of esophageal atresia among eighteen surveillance program members of the 
International Clearinghouse for Birth Defects Surveillance and Research, by pregnancy 
outcome, 1998–2007.
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